GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (NAS:NTLA) » Definitions » Operating Margin %

Intellia Therapeutics (Intellia Therapeutics) Operating Margin % : 7,297.44% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Intellia Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Intellia Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-139.89 Mil. Intellia Therapeutics's Revenue for the three months ended in Dec. 2023 was $-1.92 Mil. Therefore, Intellia Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was 7,297.44%.

Warning Sign:

Intellia Therapeutics Inc operating margin has been in a 5-year decline. The average rate of decline per year is -44.3%.

The historical rank and industry rank for Intellia Therapeutics's Operating Margin % or its related term are showing as below:

NTLA' s Operating Margin % Range Over the Past 10 Years
Min: -1420.51   Med: -266.32   Max: -195.15
Current: -1420.51


NTLA's Operating Margin % is ranked worse than
77% of 1026 companies
in the Biotechnology industry
Industry Median: -175.525 vs NTLA: -1420.51

Intellia Therapeutics's 5-Year Average Operating Margin % Growth Rate was -44.30% per year.

Intellia Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-139.89 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-515.29 Mil.


Intellia Therapeutics Operating Margin % Historical Data

The historical data trend for Intellia Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics Operating Margin % Chart

Intellia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -246.78 -235.51 -810.37 -879.04 -1,420.51

Intellia Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -811.07 -888.13 -973.47 -1,093.29 7,297.44

Competitive Comparison of Intellia Therapeutics's Operating Margin %

For the Biotechnology subindustry, Intellia Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intellia Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Operating Margin % falls into.



Intellia Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Intellia Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-515.291 / 36.275
=-1,420.51 %

Intellia Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-139.892 / -1.917
=7,297.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intellia Therapeutics  (NAS:NTLA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Intellia Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Intellia Therapeutics (Intellia Therapeutics) Business Description

Traded in Other Exchanges
Address
40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Executives
Laura Sepp-lorenzino officer: EVP, Chief Scientific Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
James Basta officer: EVP, General Counsel C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Derek Hicks officer: EVP, Chief Business Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET SUITE 130, CAMBRIDGE MA 02139
Eliana Clark officer: EVP, Chief Technical Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
David Lebwohl officer: EVP, Chief Medical Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Glenn Goddard officer: See Remarks C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
John M. Leonard director, officer: President and CEO C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
William J Chase director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
John F Crowley director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Georgia Keresty director C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Caroline Dorsa director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Jose E Rivera officer: EVP, General Counsel C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Andrew Schiermeier officer: EVP, Chief Operating Officer C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET STE 130, CAMBRIDGE MA 02139

Intellia Therapeutics (Intellia Therapeutics) Headlines

From GuruFocus

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

By Value_Insider Value_Insider 11-30-2022